Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02629692 · ClinicalTrials.gov registry record · Phase 1

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

A Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C), sponsored by Sun Pharma Advanced Research Company Limited.

Active
Registry status
Phase 1
Development phase
122
Enrollment target
20
Study locations

NCT02629692 is a Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C) that is active but no longer recruiting, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 122 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02629692, a Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C), is active but no longer recruiting, sponsored by Sun Pharma Advanced Research Company Limited.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
122 participants
Enrollment target
20
Study locations

Study Summary

Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML

Conditions Studied

Healthy (For Part A) Chronic Myeloid Leukemia (for Part B and C)

Interventions

  • DRUG Vodobatinib (K0706) capsules

Study Locations (20)

Maharashtra

  • Prince Aly Khan Hospital - Mumbai
  • Tata Memorial Hospital - Mumbai
  • Sahyadri Specialty Hospital - Pune

California

  • The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute - Downey
  • UCLA Hematologic Malignancy Program - Los Angeles

Texas

  • Baylor University Medical Center - Dallas
  • MD Anderson Cancer Center - Houston

Other

  • Cliniques Universitaires Saint-Luc - Brussels
  • Debreceni Egyetem - Debrecen

Rhone

  • Centre Léon Bérard - Lyon
  • Centre Hospitalier Lyon Sud - Pierre-Bénite

Florida

  • Mayo Clinic - Jacksonville

Georgia

  • Board of Regents of the University System of Georgia - Augusta

New York

  • Memorial Sloan Kettering Cancer Center - MAIN - New York

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2016-06-27
Est. Completion 2026-08
Phase Phase 1

Sponsor

Sun Pharma Advanced Research Company Limited

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02629692

The ClinicalTrials.gov registry entry for NCT02629692 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy (For Part A) appearing as the primary indexed condition, and to 1 intervention - of which Vodobatinib (K0706) capsules is the first listed.

NCT02629692 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Maharashtra, California, Texas.

Frequently Asked Questions

What is clinical trial NCT02629692 about?

NCT02629692 is a clinical study titled "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies". Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML

What is the current status of trial NCT02629692?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2016-06-27. Estimated completion is 2026-08.

What conditions does trial NCT02629692 study?

This clinical trial studies the following conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C).

What interventions are being tested in trial NCT02629692?

The interventions under investigation include: Vodobatinib (K0706) capsules (DRUG).

Who is sponsoring clinical trial NCT02629692?

This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02629692 being conducted?

This trial has 20 study locations across California, Florida, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Healthy (For Part A)

All registered trials for this condition

Chronic Myeloid Leukemia (for Part B and C)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.